Saxenda Pen (Liraglutide) Injection – Complete Guide for Weight Management
Saxenda (liraglutide) is a clinically approved, prescription-only injectable medication developed to support long-term weight management in adults with obesity or those who are overweight with associated health risks. Administered via a convenient pre-filled pen, Saxenda is designed for daily subcutaneous use as part of a structured weight management plan.
What is Saxenda?
Saxenda contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is authorised for adults with a body mass index (BMI) indicating obesity, or those who are overweight with comorbidities such as hypertension, type 2 diabetes, or dyslipidaemia.
The medication is supplied in prefilled injection pens at a concentration of 6 mg/ml, with each pack typically containing five pens. Saxenda is approved by regulatory authorities including the U.S. Food and Drug Administration (FDA) and reviewed under standards aligned with the European Medicines Agency (EMA).
Who Can Use Saxenda?
Saxenda may be prescribed for adults who meet the following criteria:
- BMI ≥ 30: Individuals classified as obese.
- BMI ≥ 27: Individuals who are overweight with weight-related conditions such as high blood pressure, elevated cholesterol, or type 2 diabetes.
How Saxenda Works
Saxenda works by mimicking the GLP-1 hormone, which plays a role in appetite regulation. Its key actions include:
- Appetite suppression: Reduces hunger signals in the brain.
- Increased satiety: Helps you feel fuller for longer after meals.
- Reduced calorie intake: Supports sustainable dietary changes.
These mechanisms contribute to gradual, clinically meaningful weight loss when combined with dietary and lifestyle modifications.
Benefits of Saxenda
- Supports clinically significant weight reduction
- Helps maintain long-term weight loss
- Improves obesity-related health markers
- Encourages healthier eating behaviours
Clinical studies indicate that patients using Saxenda alongside lifestyle changes achieve greater weight loss compared to placebo-treated groups.
Who Should Not Use Saxenda?
- Individuals with a personal or family history of medullary thyroid carcinoma
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Those with type 1 diabetes or diabetic ketoacidosis
Important Safety Considerations
- Monitor for symptoms of thyroid tumours (e.g., neck lump, hoarseness)
- Be aware of signs of pancreatitis (severe abdominal pain)
- Watch for gallbladder-related symptoms
- Seek immediate medical attention for persistent vomiting or severe discomfort
Common Side Effects
- Nausea
- Diarrhoea
- Constipation
- Reduced appetite
- Injection site reactions (redness, itching)
These side effects are typically mild and tend to improve as treatment continues.
Dosage and Administration
Saxenda is administered once daily via subcutaneous injection. A gradual dose escalation is recommended to improve tolerability:
- Week 1: 0.6 mg daily
- Week 2: 1.2 mg daily
- Week 3: 1.8 mg daily
- Week 4: 2.4 mg daily
- Week 5 onward: 3.0 mg daily (maintenance dose)
Missed Dose Guidance
If a dose is missed, continue with the next scheduled dose. If more than three days are missed, restart at 0.6 mg and re-escalate.
How to Use Saxenda
- Inject under the skin of the abdomen, thigh, or upper arm
- Use a new needle for each injection
- Rotate injection sites to minimise irritation
- Administer at the same time each day, with or without food
Storage Instructions
- Store unused pens in a refrigerator (2°C to 8°C)
- After first use, store at room temperature or refrigerated for up to 30 days
- Protect from excessive heat and direct light
When to Discontinue Saxenda
If you have not lost at least 5% of your initial body weight after 12 weeks on the maintenance dose (3.0 mg daily), your healthcare provider may advise discontinuing treatment.
Clinical Evidence and Guidelines
Clinical trials have demonstrated the efficacy of liraglutide in promoting weight loss and improving metabolic parameters. Guidance from NICE and the NHS supports the use of GLP-1 receptor agonists for appropriate patients.
Frequently Asked Questions
Is Saxenda a GLP-1 medication?
Yes, Saxenda is a GLP-1 receptor agonist that helps regulate appetite and reduce calorie intake.
How much weight can I lose?
Weight loss varies, but clinical data suggest an average reduction of 5–10% of body weight in many patients.
How many pens are needed monthly?
Typically, five pens are required during the first four weeks, depending on dose escalation.
Can Saxenda be used with other medications?
Always consult your healthcare provider to evaluate potential drug interactions.
Internal Links
Disclaimer
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or modifying any treatment.
References
Tags
Saxenda, Liraglutide, Weight Loss Injection, GLP-1, Obesity Treatment, Saxenda liraglutide, weight loss injection, GLP-1 agonist, obesity medication, appetite suppressant injection, daily weight loss therapy
